网络编辑平台

编辑出版

《中国临床医学》编辑部

  地址:上海市枫林路179号18号楼501室

  邮编:200032

  电话:021-60267570

  邮箱:(1)zglcyx@126.com; (2)zglcyxfb@126.com

作者园地

在线调查

您喜欢的投稿方式调查


相关下载

您所在位置:首页->过刊浏览->第18卷第6期


论著:BALB/c小鼠噁唑酮结肠炎模型的建立
Establishment of BALB/c Mice Oxazolone-Colitis Model
王学伟 杨净慧 曹勤 唐剑敏
点击:1567次 下载:0次
作者单位:上海中医药大学附属普陀医院消化内科
中文关键字:噁唑酮;BALB/c小鼠;结肠炎;溃疡性结肠炎;细胞因子
英文关键字:Oxazolone;BALB/C mice;Colitis;Ulcerative colitis;Cytokine
中文摘要:目的:建立BALB/c小鼠噁唑酮结肠炎模型,评价其作为人类溃疡性结肠炎(UC)模型的可靠性。方法:模型组第1天和第2天用3%噁唑酮溶液200 μL涂搽BALB/c小鼠皮肤以致敏,第6天用1%噁唑酮溶液150 μL行保留灌肠,对照组给予等体积乙醇溶剂涂搽皮肤、灌肠,对2组BALB/c小鼠进行疾病活动指数(DAI)评分,评估病变结肠的病理组织学炎症程度,用荧光定量逆转录聚合酶链反应(RT-PCR)法测定结肠组织IL-5和IL-13 mRNA的表达水平。结果:模型组小鼠的DAI评分和病理炎症评分显著高于对照组(P<0.05),模型组病变结肠组织IL-5和IL-13 mRNA的表达水平亦显著高于对照组(P<0.05)。结论:BALB/c小鼠噁唑酮结肠炎模型类似于人类UC,可作为研究UC的理想模型。
英文摘要:Objective: To establish BALB/c mice oxazolone-colitis model and evaluate its reliability as a model of human ulcerative colitis (UC). Methods: At day 1 and day 2 model group mice were skin-sensitized with 200 μl 3% oxazolone, and at day 6 150 μl 1% axazolone was administered intrarectally. Control group mice were skin-sensitized and intrarectally administered with equal-volume solvent of ethanol. We observed the disease activity index (DAI) of th two group, evaluated the histopathological inflammation degree of the lesions of the colon, and determined the expression levels of IL-5 and IL-13 mRNA of the colonic tissue by real time polymerase chain reaction (RT-PCR). Results: The DAI score and the histopathological inflammation score of the model group were significantly greater than that of the control group, and the expression levels of IL-5 and IL-13 mRNA of the colonic tissue of the model group were also significantly higher than that of the control group. Conclusions: BALB/c mice oxazolone-colitis model is resemble to human UC, and could be used as an ideal research platform of UC.
读者评论

      读者ID: 密码:   
我要评论:
主办单位:复旦大学附属中山医院
联系地址:上海市枫林路179号18号楼501室 邮编:200032
联系电话:021-60267570 E-Mail:(1)zglcyx@126.com; (2)zglcyxfb@126.com
版权所有©2009-2010 《中国临床医学》杂志编辑部 沪ICP备1103249号
本系统由北京菲斯特诺科技有限公司设计开发
您是本站第1269991名访问者